Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
35
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

City of Hope Medical Center

Collaborators